News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hologic, Inc. (HOLX) Loses $4 Million Patent Suit to Smith & Nephew Inc. (SNN) Over Interlace Fibroid Tech



9/6/2012 9:07:09 AM

Hologic says a Massachusetts jury ruled against it in a patent infringement lawsuit, awarding damages of $4 million over the MyoSure device Hologic acquired along with Interlace Medical. A Massachusetts jury handed Hologic (NSDQ:HOLX) a $4 million setback today in a patent infringement battle with Smith & Nephew (FTSE:SN, NYSE:SNN) over Hologic's MyoSure fibroid surgery device. The Bedford, Mass.-based women's health giant bought the lawsuit along with Interlace Medical for $125 million in early 2011. Interlace developed the MyoSure device, a hysteroscopic system designed to remove fibroids — benign tumors of the uterus — in an out-patient procedure, using a high-speed cutting blade.

Read at MassDevice
Read at RTT News
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES